NCT00969293View on ClinicalTrials.gov

Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

March 31, 2012

Conditions
Macular EdemaCentral Retinal Vein Occlusion
Interventions
DRUG

FOV2302 (Ecallantide)

"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."

Trial Locations (8)

13008

Clinique Monticelli, Marseille

21000

CHU de Dijon, Hôpital Général, Dijon

44093

CHU de Nantes, Nantes

75012

Centre Hospitalier National d'Ophthalmologies des XV-XX, Paris

75015

Hopital Lariboisiere, Paris

75571

Fondation Rothschild, Paris

80054

CHU d'Amiens, Centre Saint-Victor, Amiens

94010

Centre Intercommunal de Creteil, Créteil

Sponsors
All Listed Sponsors
lead

Fovea Pharmaceuticals SA

INDUSTRY